tetano
Editor, Senior Moderator
J Neurol
. 2021 Jan 2.
doi: 10.1007/s00415-020-10311-w. Online ahead of print.
SARS-CoV-2 infection in patients with primary central nervous system lymphoma
Alice Laurenge[SUP] 1 [/SUP], Renata Ursu[SUP] 2 [/SUP], Caroline Houillier[SUP] 1 [/SUP], Basma Abdi[SUP] 3 4 [/SUP], Gianpiero Tebano[SUP] 5 [/SUP], Cyril Quemeneur[SUP] 6 [/SUP], Sylvain Choquet[SUP] 7 [/SUP], Roberta Di Blasi[SUP] 8 [/SUP], Fernando Lozano[SUP] 1 [/SUP], Andrea Morales[SUP] 1 [/SUP], Alberto Dur?n-Pe?a[SUP] 1 [/SUP], Lila Sirven-Villaros[SUP] 2 [/SUP], Bertrand Mathon[SUP] 9 [/SUP], Karima Mokhtari[SUP] 10 [/SUP], Franck Bielle[SUP] 10 [/SUP], Nadine Martin-Duverneuil[SUP] 11 [/SUP], Jean-Yves Delattre[SUP] 1 [/SUP], Anne-Genevi?ve Marcelin[SUP] 3 4 [/SUP], Val?rie Pourcher[SUP] 4 5 [/SUP], Agusti Alentorn[SUP] 1 [/SUP], Ahmed Idbaih[SUP] 1 [/SUP], Antoine F Carpentier[SUP] 2 [/SUP], V?ronique Leblond[SUP] 7 [/SUP], Kh? Hoang-Xuan[SUP] 1 [/SUP], Mehdi Touat[SUP] 12 [/SUP]
Affiliations
Abstract
Background: Cancer patients may be at higher risk for severe coronavirus infectious disease-19 (COVID-19); however, the outcome of Primary Central Nervous System Lymphoma (PCNSL) patients with SARS-CoV-2 infection has not been described yet.
Methods: We conducted a retrospective study within the Lymphomes Oculo-C?r?braux national network (LOC) to assess the clinical characteristics and outcome of SARS-CoV-2 infection in PCNSL patients (positive real-time polymerase chain reaction of nasopharyngeal swab or evocative lung computed tomography scan). We compared clinical characteristics between patients with severe (death and/or intensive care unit admission) and mild disease.
Results: Between March and May 2020, 13 PCNSL patients were diagnosed with SARS-CoV-2 infection, 11 (85%) of whom were undergoing chemotherapy at the time of infection. The mortality rate was 23% (3/13), and two additional patients (15%) required mechanical ventilation. Two patients (15%) had no COVID-19 symptoms. History of diabetes mellitus was more common in severe patients (3/5 vs 0/8, p = 0.03). Two patients recovered from COVID-19 after mechanical ventilation during more than two weeks and resumed chemotherapy. In all, chemotherapy was resumed after COVID-19 recovery in nine patients (69%) after a median delay of 16 days (range 3-32), none of whom developed unusual chemotherapy complication nor SARS-Cov2 reactivation.
Conclusion: This preliminary analysis suggests that, while being at higher risk be for severe illness, PCNSL patients with COVID-19 might be treated maximally especially if they achieved oncological response at the time of SARS-CoV-2 infection. Chemotherapy might be resumed without prolonged delay in PCNSL patients with COVID-19.
Keywords: COVID-19; PCNSL.
. 2021 Jan 2.
doi: 10.1007/s00415-020-10311-w. Online ahead of print.
SARS-CoV-2 infection in patients with primary central nervous system lymphoma
Alice Laurenge[SUP] 1 [/SUP], Renata Ursu[SUP] 2 [/SUP], Caroline Houillier[SUP] 1 [/SUP], Basma Abdi[SUP] 3 4 [/SUP], Gianpiero Tebano[SUP] 5 [/SUP], Cyril Quemeneur[SUP] 6 [/SUP], Sylvain Choquet[SUP] 7 [/SUP], Roberta Di Blasi[SUP] 8 [/SUP], Fernando Lozano[SUP] 1 [/SUP], Andrea Morales[SUP] 1 [/SUP], Alberto Dur?n-Pe?a[SUP] 1 [/SUP], Lila Sirven-Villaros[SUP] 2 [/SUP], Bertrand Mathon[SUP] 9 [/SUP], Karima Mokhtari[SUP] 10 [/SUP], Franck Bielle[SUP] 10 [/SUP], Nadine Martin-Duverneuil[SUP] 11 [/SUP], Jean-Yves Delattre[SUP] 1 [/SUP], Anne-Genevi?ve Marcelin[SUP] 3 4 [/SUP], Val?rie Pourcher[SUP] 4 5 [/SUP], Agusti Alentorn[SUP] 1 [/SUP], Ahmed Idbaih[SUP] 1 [/SUP], Antoine F Carpentier[SUP] 2 [/SUP], V?ronique Leblond[SUP] 7 [/SUP], Kh? Hoang-Xuan[SUP] 1 [/SUP], Mehdi Touat[SUP] 12 [/SUP]
Affiliations
- PMID: 33387015
- DOI: 10.1007/s00415-020-10311-w
Abstract
Background: Cancer patients may be at higher risk for severe coronavirus infectious disease-19 (COVID-19); however, the outcome of Primary Central Nervous System Lymphoma (PCNSL) patients with SARS-CoV-2 infection has not been described yet.
Methods: We conducted a retrospective study within the Lymphomes Oculo-C?r?braux national network (LOC) to assess the clinical characteristics and outcome of SARS-CoV-2 infection in PCNSL patients (positive real-time polymerase chain reaction of nasopharyngeal swab or evocative lung computed tomography scan). We compared clinical characteristics between patients with severe (death and/or intensive care unit admission) and mild disease.
Results: Between March and May 2020, 13 PCNSL patients were diagnosed with SARS-CoV-2 infection, 11 (85%) of whom were undergoing chemotherapy at the time of infection. The mortality rate was 23% (3/13), and two additional patients (15%) required mechanical ventilation. Two patients (15%) had no COVID-19 symptoms. History of diabetes mellitus was more common in severe patients (3/5 vs 0/8, p = 0.03). Two patients recovered from COVID-19 after mechanical ventilation during more than two weeks and resumed chemotherapy. In all, chemotherapy was resumed after COVID-19 recovery in nine patients (69%) after a median delay of 16 days (range 3-32), none of whom developed unusual chemotherapy complication nor SARS-Cov2 reactivation.
Conclusion: This preliminary analysis suggests that, while being at higher risk be for severe illness, PCNSL patients with COVID-19 might be treated maximally especially if they achieved oncological response at the time of SARS-CoV-2 infection. Chemotherapy might be resumed without prolonged delay in PCNSL patients with COVID-19.
Keywords: COVID-19; PCNSL.